StockData

Addex Therapeutics vs Altimmune

ADXN and ALT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADXN and ALT compare

Altimmune scores higher on the StockData Score (4 against 0 for Addex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADXNALT
Size and price
Market cap–$298M
Share price$3.50$1.53
Change, 1 year−58.7%−63.3%
Change, 5 years−97.5%−85.3%
Beta (5Y)1.951.90
Employees313
StockData Score
Total score04 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score02 (better)
Dividend score00
Valuation
P/B–0.6×
FCF yield–−25.7%
Growth
Revenue growth (TTM)−92.6%–
Revenue growth, 5Y average−61.6% (better)−65.3%
EPS growth (TTM)−186%–
Profitability
Operating margin−9391%–
FCF margin−7244%–
Return on equity–−28.9%
Return on invested capital–−90.4%
Financial health
Debt / equity–0.07
Interest coverage−181.0×−28.3× (better)
Current ratio0.7626.78 (better)
Altman Z-score–1.63
Piotroski F-score–4
Dividends and buybacks
Buyback yield–−37.0%
Shareholder yield–−37.0%
Ownership
Held by institutions0.00%77.9%
Held by insiders15.5%0.56%
Insider net buying, 12 months–$452K
Superinvestors holding–1
Short interest, % of float–21.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.